Literature DB >> 21753163

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.

C Marras1, B Schüle, B Schuele, R P Munhoz, E Rogaeva, J W Langston, M Kasten, C Meaney, C Klein, P M Wadia, S-Y Lim, R S-I Chuang, C Zadikof, T Steeves, K M Prakash, R M A de Bie, G Adeli, T Thomsen, K K Johansen, H A Teive, A Asante, W Reginold, A E Lang.   

Abstract

OBJECTIVES: Using a family study design, we describe the motor and nonmotor phenotype in probands with LRRK2 G2019S mutations and family members and compare these individuals to patients with idiopathic Parkinson disease (iPD) and unrelated controls.
METHODS: Probands with G2019S mutations and their first-degree relatives, subjects with iPD, and unrelated control subjects were identified from 4 movement disorders centers. All underwent neurologic examinations and tests of olfaction, color vision, anxiety, and depression inventories.
RESULTS: Tremor was more often a presenting feature among 25 individuals with LRRK2-associated PD than among 84 individuals with iPD. Subjects with LRRK2-PD had better olfactory identification compared with subjects with iPD, higher Beck Depression Inventory scores, and higher error scores on Farnsworth-Munsell 100-Hue test of color discrimination. Postural or action tremor was more common among 29 nonmanifesting mutation carriers compared with 53 noncarriers within the families. Nonparkinsonian family members had higher Unified Parkinson's Disease Rating Scale motor scores, more constipation, and worse color discrimination than controls, regardless of mutation status.
CONCLUSIONS: Although tremor is a more common presenting feature of LRRK2-PD than iPD and some nonmotor features differed in degree, the phenotype is largely overlapping. Postural or action tremor may represent an early sign. Longitudinal evaluation of a large sample of nonmanifesting carriers will be required to describe any premotor phenotype that may allow early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753163      PMCID: PMC3140802          DOI: 10.1212/WNL.0b013e318227042d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  LRRK2 gene in Parkinson disease: mutation analysis and case control association study.

Authors:  C Paisán-Ruíz; A E Lang; T Kawarai; C Sato; S Salehi-Rad; G K Fisman; T Al-Khairallah; P St George-Hyslop; A Singleton; E Rogaeva
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.

Authors:  Dena G Hernandez; Coro Paisán-Ruíz; Aideen McInerney-Leo; Shushant Jain; Andreas Meyer-Lindenberg; E Whitney Evans; Karen F Berman; Janel Johnson; Georg Auburger; Alejandro A Schäffer; Grisel J Lopez; Robert L Nussbaum; Andrew B Singleton
Journal:  Ann Neurol       Date:  2005-03       Impact factor: 10.422

4.  The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia.

Authors:  E L Teng; K Hasegawa; A Homma; Y Imai; E Larson; A Graves; K Sugimoto; T Yamaguchi; H Sasaki; D Chiu
Journal:  Int Psychogeriatr       Date:  1994       Impact factor: 3.878

5.  High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.

Authors:  Joaquim J Ferreira; Leonor Correia Guedes; Mário Miguel Rosa; Miguel Coelho; Marina van Doeselaar; Dorothea Schweiger; Alessio Di Fonzo; Ben A Oostra; Cristina Sampaio; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 6.  Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain.

Authors:  Connie Marras; Anthony Lang
Journal:  Neurology       Date:  2008-05-20       Impact factor: 9.910

7.  A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.

Authors:  Ebba Lohmann; Laurence Leclere; Francesca De Anna; Suzanne Lesage; Bruno Dubois; Yves Agid; Alexandra Dürr; Alexis Brice
Journal:  Parkinsonism Relat Disord       Date:  2008-08-21       Impact factor: 4.891

8.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

9.  A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease.

Authors:  Kenya Nishioka; Mounir Kefi; Barbara Jasinska-Myga; Christian Wider; Carles Vilariño-Güell; Owen A Ross; Michael G Heckman; Lefkos T Middleton; Lianna Ishihara-Paul; Rachel A Gibson; Rim Amouri; Samia Ben Yahmed; Samia Ben Sassi; Mourad Zouari; Ghada El Euch; Matthew J Farrer; Faycal Hentati
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-02       Impact factor: 10.154

10.  The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Authors:  Jeanne C Latourelle; Mei Sun; Mark F Lew; Oksana Suchowersky; Christine Klein; Lawrence I Golbe; Margery H Mark; John H Growdon; G Frederick Wooten; Ray L Watts; Mark Guttman; Brad A Racette; Joel S Perlmutter; Anwar Ahmed; Holly A Shill; Carlos Singer; Stefano Goldwurm; Gianni Pezzoli; Michela Zini; Marie H Saint-Hilaire; Audrey E Hendricks; Sally Williamson; Michael W Nagle; Jemma B Wilk; Tiffany Massood; Karen W Huskey; Jason M Laramie; Anita L DeStefano; Kenneth B Baker; Ilia Itin; Irene Litvan; Garth Nicholson; Alastair Corbett; Martha Nance; Edward Drasby; Stuart Isaacson; David J Burn; Patrick F Chinnery; Peter P Pramstaller; Jomana Al-hinti; Anette T Moller; Karen Ostergaard; Scott J Sherman; Richard Roxburgh; Barry Snow; John T Slevin; Franca Cambi; James F Gusella; Richard H Myers
Journal:  BMC Med       Date:  2008-11-05       Impact factor: 8.775

View more
  62 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 2.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

3.  Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?

Authors:  Elena Antelmi; Giovanni Rizzo; Margherita Fabbri; Sabina Capellari; Cesa Scaglione; Paolo Martinelli
Journal:  J Neurol       Date:  2014-07-03       Impact factor: 4.849

4.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

5.  Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants.

Authors:  Da-Wei Li; Zhuqin Gu; Chaodong Wang; Jinghong Ma; Bei-Sha Tang; Sheng-Di Chen; Piu Chan
Journal:  J Neural Transm (Vienna)       Date:  2014-07-26       Impact factor: 3.575

6.  Mutant of leucine-rich repeat kinase 2 is not associated with non-motor symptoms in Chinese Parkinson's disease patients.

Authors:  Maolin Hao; Ning Pan; Qinghua Zhang; Xiaohong Wang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

7.  Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.

Authors:  Claudia Carricarte Naranjo; Connie Marras; Naomi P Visanji; David J Cornforth; Lazaro Sanchez-Rodriguez; Birgitt Schüle; Samuel M Goldman; Mario Estévez; Phyllis K Stein; Anthony E Lang; Herbert F Jelinek; Andrés Machado
Journal:  Clin Auton Res       Date:  2019-08-23       Impact factor: 4.435

8.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Authors:  Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 9.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 10.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.